Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1792-1797

  Kattan, Michael W ^a   Eastham, James A ^a   Wheeler, Thomas M ^c   Maru, Norio ^c   Scardino, Peter T ^a   Erbersdobler, Andreas ^b   Graefen, Markus ^a,b   Huland, Hartwig ^b   Koh, Hideshige ^a   Shariat, Shahrokh F ^c   Slawin, Kevin M ^c   Ohori, Makoto ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Models, statistical; Prostatic neoplasms, biopsy, prognosis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NOMOGRAM; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; STATISTICAL MODEL; TUMOR VOLUME;

EID: 0141919742     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091806.70171.41     Document Type: Article

References (21)

1. Jemal, A., Thomas, A., Murray, T. and Thun, M.: Cancer statistics, 2002. CA Cancer J Clin, 52: 23, 2002
2. Ohori, M., Wheeler, T. M., Dunn, J. K., Stamey, T. A. and Scardino, P. T.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol, 152: 1714, 1994
3. Noguchi, M., Stamey, T. A., McNeal, J. E. and Yemoto, C. M.: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol, 166: 104, 2001
4. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
5. Epstein, J. I., Walsh, P. C., Carmichael, M. J. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271: 368, 1994
6. Carter, H. B., Sauvageot, J., Walsh, P. C. and Epstein, J. I.: Prospective evaluation of men with stage TIC adenocarcinoma of the prostate. J Urol, 157: 2206, 1997
7. Goto, Y., Ohori, M., Arakawa, A., Kattan, M. W., Wheeler, T. M. and Scardino, P. T.: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol, 156: 1059, 1996
8. Epstein, J. I., Chan, D. W., Sokoll, L. J., Walsh, P. C., Cox, J. L., Rittenhouse, H. et al: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol, 160: 2407, 1998
9. Aihara, M., Wheeler, T. M., Ohori, M. and Scardino, P. T.: Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology, 43: 60, 1994
10. Kronmal, R. A.: Spurious correlation and the fallacy of the ratio standard revisited. J R Statist Soc, 156: 379, 1993
11. Harrell, F. E., Jr.: Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag, p. 568, 2001
12. Scardino, P. T., Weaver, R. and Hudson, M. A.: Early detection of prostate cancer. Hum Pathol, 23: 211, 1992
13. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W. et al: Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. Bethesda, MD: National Institutes of Health, Pub. No. 99-4543, 1999
14. Etzioni, R., Penson, D. F., Legler, J. M., Di Tommaso, D., Boer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002
15. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W. and Scardino, P. T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528, 2002
16. DiGiuseppe, J. A., Sauvageot, J. and Epstein, J. I.: Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol, 21: 174, 1997
17. Carter, H. B., Walsh, P. C., Landis, P. and Epstein, J. I.: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol, 167: 1231, 2002
18. Choo, R., Klotz, L., Danjoux, C., Morton, G. C., DeBoer, G., Szumacher, E. et al: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol, 167: 1664, 2002
19. Zietman, A. L., Thakral, H., Wilson, L. and Schellhammer, P.: Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol, 166: 1702, 2001
20. Albertsen, J. L., Hanley, J. A., Gleason, D. F. and Barry, M. J.: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280: 975, 1998
21. Epstein, J. I., Walsh, P. C., Akingba, G. and Carter, H. B.: The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol, 162: 1649, 1999